Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
- Posted on June 8, 2026
- By Bing News
- 0 Views
- 1 min read
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
ZURICH, June 8 (Reuters) - Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday. • The deal focuses on blood cancer drug bexobrutideg, which degrades targeted proteins and is planned to enter a phase III clinical trial initiation for chronic lymphocytic leukaemia (CLL) in the
